Table 3.
FMD values at baseline and during follow-up
Study 1 | Study 2 | |||
---|---|---|---|---|
Beverage A | Beverage B | Beverage A | Beverage C | |
Systolic blood pressure, mmHg | ||||
Baseline | 130 ± 11 | 131 ± 11 | 128 ± 13 | 130 ± 14 |
1 h | 131 ± 13 | 128 ± 11 | 129 ± 12 | 132 ± 16 |
2 h | 130 ± 12 | 129 ± 13 | 128 ± 16 | 129 ± 16 |
Chlorogenic acid, ng/mL | ||||
Baseline | 0.7 ± 2.0 | 1.1 ± 3.0 | 1.1 ± 2.7 | 0.7 ± 2.8 |
1 h | 54.0 ± 20.5* | 56.5 ± 22.7* | 51.5 ± 22.5* | 0.3 ± 1.3† |
2 h | 50.3 ± 16.0* | 55.1 ± 23.3* | 56.7 ± 21.2* | 0.3 ± 1.2† |
Triglycerides, mg/dL | ||||
Baseline | 124 ± 63 | 117 ± 65 | 121 ± 67 | 111 ± 49 |
1 h | 159 ± 76* | 143 ± 72* | 140 ± 66* | 132 ± 48* |
2 h | 181 ± 90* | 188 ± 104* | 174 ± 74* | 167 ± 64* |
Glucose, mg/dL | ||||
Baseline | 95 ± 10 | 93 ± 6 | 92 ± 8 | 92 ± 7 |
1 h | 140 ± 32* | 139 ± 32* | 124 ± 23* | 130 ± 22* |
2 h | 120 ± 29* | 122 ± 24* | 112 ± 16* | 110 ± 18* |
Insulin, µIU/L | ||||
Baseline | 7 ± 5 | 6 ± 4 | 6 ± 4 | 6 ± 3 |
1 h | 55 ± 39* | 51 ± 36* | 42 ± 39* | 42 ± 27* |
2 h | 41 ± 28* | 45 ± 46* | 26 ± 22* | 27 ± 25* |
8-Isoprostane, pg/mL | ||||
Baseline | 75 ± 48 | 55 ± 23 | 88 ± 67 | 73 ± 57 |
1 h | 56 ± 41 | 59 ± 46 | 75 ± 67* | 55 ± 23 |
2 h | 73 ± 60 | 69 ± 74 | 72 ± 59* | 64 ± 32 |
High-sensitivity C-reactive protein, mg/dL | ||||
Baseline | 0.10 ± 0.17 | 0.05 ± 0.04 | 0.07 ± 0.07 | 0.08 ± 0.17 |
1 h | 0.10 ± 0.17 | 0.05 ± 0.04 | 0.07 ± 0.07 | 0.09 ± 0.21 |
2 h | 0.10 ± 0.16 | 0.05 ± 0.04 | 0.07 ± 0.07 | 0.11 ± 0.25 |
FMD, % | ||||
Baseline | 4.5 ± 4.0 | 5.4 ± 4.8 | 3.1 ± 3.6 | 4.2 ± 3.6 |
1 h | 5.4 ± 4.5* | 4.9 ± 4.6 | 4.9 ± 2.1* | 4.1 ± 3.3 |
2 h | 6.0 ± 2.4* | 6.4 ± 4.4 | 4.6 ± 3.4* | 3.8 ± 3.7 |
*P < 0.05 vs. baseline
†P < 0.05 vs. Beverage A